DEM BioPharma

Private

Cambridge, MassachusettsHealthcare & Life Scienceshttps://dembiopharma.com/

Last Round

Series A

Jun 23, 2022

Total Funding Raised

$70M

Company Overview

DEM BioPharma is a biotechnology company that develops innovative immunotherapeutics targeting novel signals on cancer cells and macrophages to eliminate solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologycancer immunotherapydon't eat me signalsphagocytosisdrug discovery platformantibody-drug conjugateADCfunctional genomicsCRISPR screeningcheckpoint inhibitormacrophage therapypre-clinical biotechtumor immune evasionbiotech startupinnate immunity

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DEM BioPharma Comps

Public and private peers based on sector, stage, and business model.

DEM BioPharma comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

DEM BioPharma Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Jun 23, 2022

View all Funding Rounds

Key People

Founding team and executive leadership

Nenad Grmusa

Chief Executive Officer

Executive Team

DEM BioPharma Investors

Notable investors and investment history

DEM BioPharma investors
Investor	Rounds
Dean Capital Investments Management	Series A
Alexandria Venture Investments	Series A
Emerson Collective	Series A
Astellas Venture Management	Series A
Pfizer Ventures	Series A
Pfizer	Series A
Longwood Fund	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 6, 2026
Presenting product DEM301 at the 2026 ASCO Gastrointestinal Cancers Symposium.

View all signals

DEM BioPharma Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

DEM BioPharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about DEM BioPharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts

Employee Range20

Year Founded2022

Last FundingJun 23, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.